TOKYO -- Shares of Japanese drugmaker Eisai fell 13% in Tokyo on Monday following European authority's surprise rejection of its Alzheimer's drug last week.
"[T]he benefits of treatment are not large enough to outweigh the risks associated with Leqembi," said the European Medicines Agency (EMA) in an opinion issued on July 25. Leqembi can have side effects, such as headache and swelling in areas of the brain.
